Effects of Dutasteride on Prostate Carcinoma Primary Cultures: A Comparative Study With Finasteride and MK386

Journal of Urology

Volumn 180, Issue 1, 2008, Pages 367-372

  Festuccia, Claudio ^a   Gravina, Giovanni Luca ^b   Muzi, Paola ^a   Pomante, Roberto ^c   Angelucci, Adriano ^a   Vicentini, Carlo ^b   Bologna, Mauro ^a,b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c G Mazzini Hospital   (Italy)

Author keywords

cholestenone 5 alpha reductase; dutasteride; prostate; prostatic neoplasms; receptors, androgen

Indexed keywords

4,7BETA DIMETHYL 4 AZACHOLESTAN 3 ONE; BIOCHEMICAL MARKER; DUTASTERIDE; FINASTERIDE;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CELL CULTURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; SAMPLE; TUMOR CELL;

AGED; AZASTEROIDS; CELL PROLIFERATION; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR CELLS, CULTURED;

EID: 46549083556     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.02.036     Document Type: Article

References (20)

1. Russell D.W., and Wilson J.D. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 63 (1994) 25
2. Thomas L.N., Lazier C.B., Gupta R., Norman R.W., Troyer D.A., O'Brien S.P., et al. Differential alterations in 5 alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63 (2005) 231
3. Thomas L.N., Douglas R.C., Vessey J.P., Gupta R., Fontaine D., Norman R.W., et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170 (2003) 2019
4. Titus M.A., Gregory C.W., Ford III O.H., Schell M.J., Maygarden S.J., and Mohler J.L. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4365
5. Thompson I.M., Pauler Ankerst D., Chi C., Goodman P.J., Tangen C.M., Lippman S.M., et al. Prediction of prostate cancer for patients receiving finasteride: results from the prostate cancer prevention trial. J Clin Oncol 25 (2007) 3076
6. Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., and Isaacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 (2006) 4072
7. Moss M.L., Kuzmic P., Stuart J.D., Tian G., Peranteau A.G., Frye S.V., et al. Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism. Biochemistry 35 (1996) 3457
8. Bologna M., Muzi P., Biordi L., Festuccia C., and Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 45 (1995) 282
9. Festuccia C., Angelucci A., Gravina G.L., Muzi P., Vicentini C., and Bologna M. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. J Cancer Res Clin Oncol 131 (2005) 243
10. Lazier C.B., Thomas L.N., Douglas R.C., Vessey J.P., and Rittmaster R.S. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58 (2004) 130
11. McCrohan M.A., Morrissey C., O'Keane C., Mulligan N., Watson C., Smith J., et al. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 106 (2006) 2743
12. Festuccia C., Angelucci A., Gravina G.L., Muzi P., Miano R., Vicentini C., et al. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. Int J Oncol 26 (2005) 1353
13. Thorpe J.F., Jain S., Marczylo T.H., Gescher A.J., Steward W.P., and Mellon J.K. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 89 (2007) 207
14. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
15. Fleshner N., Gomella L.G., Cookson M.S., Finelli A., Evans A., Taneja S., et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 28 (2007) 763
16. Gleave M., Qian J., Andreou C., Pommerville P., Chin J., Casey R., et al. The effects of the dual 5a-reductase inhibitor dutasteride on localized prostate cancer-results from a 4 month pre-radical prostatectomy study. Prostate 66 (2006) 1674
17. Heer R., Robson C.N., Shenton B.K., and Leung H.Y. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J Cell Physiol 212 (2007) 572
18. Yoshimoto M., Cutz J.C., Nuin P.A., Joshua A.M., Bayani J., Evans A.J., et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169 (2006) 128
19. Bertram J., Peacock J.W., Fazli L., Mui A.L., Chung S.W., Cox M.E., et al. Loss of PTEN is associated with progression to androgen independence. Prostate 66 (2006) 895
20. Nakamura Y., Suzuki T., Nakabayashi M., Endoh M., Sakamoto K., Mikami Y., et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12 (2005) 101